Date Title Document
Valeant's Patient Access And Pricing Committee Announces Pricing For SILIQ™ (Brodalumab) As The Lowest Priced Injectable Biologic For Moderate-To-Severe Plaque Psoriasis Date 04/21/17 Title Valeant's Patient Access And Pricing Committee Announces Pricing For SILIQ™ (Brodalumab) As The Lowest Priced Injectable Biologic For Moderate-To-Severe Plaque Psoriasis Download PDF
Valeant Pharmaceuticals Announces 2017 Annual Meeting Of Shareholders Webcast And Q1 2017 Financial Results Conference Call Date 04/10/17 Title Valeant Pharmaceuticals Announces 2017 Annual Meeting Of Shareholders Webcast And Q1 2017 Financial Results Conference Call Download PDF
Bausch + Lomb Receives 510(k) Clearance From FDA For Stellaris Elite™ Next-Generation Phacoemulsification Platform Date 04/06/17 Title Bausch + Lomb Receives 510(k) Clearance From FDA For Stellaris Elite™ Next-Generation Phacoemulsification Platform Download PDF
Bausch + Lomb ULTRA® for Astigmatism Contact Lenses Introduced Date 03/30/17 Title Bausch + Lomb ULTRA® for Astigmatism Contact Lenses Introduced Download PDF
Valeant Completes Refinancing Transactions Date 03/21/17 Title Valeant Completes Refinancing Transactions Download PDF
Valeant Announces the Early Results of Tender Offers for Its 6.75% Senior Notes Due 2018 Date 03/20/17 Title Valeant Announces the Early Results of Tender Offers for Its 6.75% Senior Notes Due 2018 Download PDF
Bausch + Lomb And Nicox Announce PDUFA Date For Novel Glaucoma Candidate Latanoprostene Bunod Date 03/20/17 Title Bausch + Lomb And Nicox Announce PDUFA Date For Novel Glaucoma Candidate Latanoprostene Bunod Download PDF
Bausch + Lomb Introduces Biotrue® ONEday For Astigmatism Contact Lenses Date 03/15/17 Title Bausch + Lomb Introduces Biotrue® ONEday For Astigmatism Contact Lenses Download PDF
Valeant Receives Lender Consent For Refinancing And Amendment Of Credit Agreement Date 03/10/17 Title Valeant Receives Lender Consent For Refinancing And Amendment Of Credit Agreement Download PDF
Valeant Announces Upsizing Of Cash Tender Offer For Its 6.75% Senior Notes Due 2018 Date 03/10/17 Title Valeant Announces Upsizing Of Cash Tender Offer For Its 6.75% Senior Notes Due 2018 Download PDF
Valeant Announces Pricing And Upsize Of Private Offering Of Senior Secured Notes Date 03/10/17 Title Valeant Announces Pricing And Upsize Of Private Offering Of Senior Secured Notes Download PDF
Valeant Announces Launch Of Private Offering Of Senior Secured Notes Date 03/09/17 Title Valeant Announces Launch Of Private Offering Of Senior Secured Notes Download PDF
Valeant Commences Cash Tender Offer For Up To $600,000,000 Outstanding Principal Amount Of Its 6.75% Senior Notes Due 2018 Date 03/07/17 Title Valeant Commences Cash Tender Offer For Up To $600,000,000 Outstanding Principal Amount Of Its 6.75% Senior Notes Due 2018 Download PDF
Valeant Completes Approximately $1.1 Billion Pay Down Of Senior Secured Term Loans From Divestitures; To Seek Refinancing And Amendment Of Credit Agreement Date 03/06/17 Title Valeant Completes Approximately $1.1 Billion Pay Down Of Senior Secured Term Loans From Divestitures; To Seek Refinancing And Amendment Of Credit Agreement Download PDF
Valeant Pharmaceuticals Completes Sale Of CeraVe, AcneFree And AMBI Skincare Brands To L'Oréal Date 03/03/17 Title Valeant Pharmaceuticals Completes Sale Of CeraVe, AcneFree And AMBI Skincare Brands To L'Oréal Download PDF
Valeant Pharmaceuticals Corrects Misleading Report About Salix Investigation Date 03/01/17 Title Valeant Pharmaceuticals Corrects Misleading Report About Salix Investigation Download PDF
Valeant Reports Fourth Quarter And Full Year 2016 Financial Results And Provides 2017 Guidance Date 02/28/17 Title Valeant Reports Fourth Quarter And Full Year 2016 Financial Results And Provides 2017 Guidance Download PDF
Valeant Announces Deployment Of Expanded Salix Sales Force To Capture Untapped Market Opportunity Date 02/27/17 Title Valeant Announces Deployment Of Expanded Salix Sales Force To Capture Untapped Market Opportunity Download PDF
Bausch + Lomb And Nicox Resubmit US New Drug Application For Novel Glaucoma Candidate Latanoprostene Bunod Date 02/27/17 Title Bausch + Lomb And Nicox Resubmit US New Drug Application For Novel Glaucoma Candidate Latanoprostene Bunod Download PDF
Obagi Medical Products Announces Collaboration With Suzan Obagi, M.D., And Nextcell Medical To Introduce New Line Of Products Date 02/23/17 Title Obagi Medical Products Announces Collaboration With Suzan Obagi, M.D., And Nextcell Medical To Introduce New Line Of Products Download PDF
Valeant Pharmaceuticals And EyeGate Enter Into Licensing Agreement For EGP-437 Combination Product In Post-Operative Pain And Inflammation In Ocular Surgery Patients Date 02/21/17 Title Valeant Pharmaceuticals And EyeGate Enter Into Licensing Agreement For EGP-437 Combination Product In Post-Operative Pain And Inflammation In Ocular Surgery Patients Download PDF
Valeant Receives FDA Approval Of SILIQ™ (Brodalumab) For Moderate-To-Severe Plaque Psoriasis Date 02/16/17 Title Valeant Receives FDA Approval Of SILIQ™ (Brodalumab) For Moderate-To-Severe Plaque Psoriasis Download PDF
Valeant Pharmaceuticals To Participate At Healthcare Conferences Date 02/13/17 Title Valeant Pharmaceuticals To Participate At Healthcare Conferences Download PDF
Valeant To Hold Conference Call To Present Fourth Quarter And Full Year 2016 Results And Announce 2017 Guidance Date 01/30/17 Title Valeant To Hold Conference Call To Present Fourth Quarter And Full Year 2016 Results And Announce 2017 Guidance Download PDF
Bausch + Lomb Launches Expanded Parameters For Bausch + Lomb ULTRA® For Presbyopia Contact Lenses Date 01/10/17 Title Bausch + Lomb Launches Expanded Parameters For Bausch + Lomb ULTRA® For Presbyopia Contact Lenses Download PDF
Valeant Pharmaceuticals Announces Results Of Second Phase 3 Study For Psoriasis Treatment IDP-118 Date 01/10/17 Title Valeant Pharmaceuticals Announces Results Of Second Phase 3 Study For Psoriasis Treatment IDP-118 Download PDF
Valeant To Sell CeraVe, AcneFree And AMBI Skincare Brands To L'Oreal For $1.3 Billion Date 01/10/17 Title Valeant To Sell CeraVe, AcneFree And AMBI Skincare Brands To L'Oreal For $1.3 Billion Download PDF
Valeant To Sell Dendreon To Sanpower Group For $819.9 Million In Cash Date 01/09/17 Title Valeant To Sell Dendreon To Sanpower Group For $819.9 Million In Cash Download PDF
Valeant Pharmaceuticals To Present At The 35th Annual J.P. Morgan Healthcare Conference Date 01/04/17 Title Valeant Pharmaceuticals To Present At The 35th Annual J.P. Morgan Healthcare Conference Download PDF
Valeant Pharmaceuticals Announces Addition Of Richard U. DeSchutter To Its Board Of Directors Date 01/04/17 Title Valeant Pharmaceuticals Announces Addition Of Richard U. DeSchutter To Its Board Of Directors Download PDF
Valeant Appoints William D. Humphries As EVP, Dermatology Date 12/12/16 Title Valeant Appoints William D. Humphries As EVP, Dermatology Download PDF
Valeant Pharmaceuticals Announces Phase 3 Results For Psoriasis Treatment IDP-118 Date 12/08/16 Title Valeant Pharmaceuticals Announces Phase 3 Results For Psoriasis Treatment IDP-118 Download PDF
Valeant Announces The Initiation Of A Primary Care Sales Force For Xifaxan® And Relistor® Date 11/29/16 Title Valeant Announces The Initiation Of A Primary Care Sales Force For Xifaxan® And Relistor® Download PDF
Valeant Comments On Issued Philidor Criminal Charges Date 11/17/16 Title Valeant Comments On Issued Philidor Criminal Charges Download PDF
Valeant Pharmaceuticals To Participate In Healthcare Conferences Date 11/10/16 Title Valeant Pharmaceuticals To Participate In Healthcare Conferences Download PDF
Valeant Reports Third Quarter 2016 Financial Results Date 11/08/16 Title Valeant Reports Third Quarter 2016 Financial Results Download PDF
Valeant Pharmaceuticals Comments On Press Report Regarding Its Gastroenterology Business Unit Date 11/01/16 Title Valeant Pharmaceuticals Comments On Press Report Regarding Its Gastroenterology Business Unit Download PDF
Valeant Pharmaceuticals Comments On Press Report Date 10/31/16 Title Valeant Pharmaceuticals Comments On Press Report Download PDF
Valeant Announces Third Quarter Financial Results Date And Conference Call Details Date 10/17/16 Title Valeant Announces Third Quarter Financial Results Date And Conference Call Details Download PDF
Valeant Patient Access And Pricing Committee Comments On Recent Pricing Action Decisions Date 10/14/16 Title Valeant Patient Access And Pricing Committee Comments On Recent Pricing Action Decisions Download PDF
Valeant Appoints Louis W. Yu, Ph.D. As Chief Quality Officer Date 10/06/16 Title Valeant Appoints Louis W. Yu, Ph.D. As Chief Quality Officer Download PDF
Valeant Comments On Discount And Rebate Program For Nitropress And Isuprel Date 09/16/16 Title Valeant Comments On Discount And Rebate Program For Nitropress And Isuprel Download PDF
Valeant And Progenics Announce The U.S. Commercial Launch Of FDA-Approved Relistor® Tablets Date 09/06/16 Title Valeant And Progenics Announce The U.S. Commercial Launch Of FDA-Approved Relistor® Tablets Download PDF
Valeant Pharmaceuticals To Participate In September Healthcare Conferences Date 08/30/16 Title Valeant Pharmaceuticals To Participate In September Healthcare Conferences Download PDF
Valeant Pharmaceuticals Appoints Paul S. Herendeen As Executive Vice President, Finance And Chief Financial Officer Date 08/22/16 Title Valeant Pharmaceuticals Appoints Paul S. Herendeen As Executive Vice President, Finance And Chief Financial Officer Download PDF
Valeant Pharmaceuticals Receives Lender Consent For Credit Facility Amendment Date 08/18/16 Title Valeant Pharmaceuticals Receives Lender Consent For Credit Facility Amendment Download PDF
Valeant Pharmaceuticals Comments On SDNY Investigation Date 08/10/16 Title Valeant Pharmaceuticals Comments On SDNY Investigation Download PDF
Valeant Pharmaceuticals Reports Second Quarter 2016 Financial Results Date 08/09/16 Title Valeant Pharmaceuticals Reports Second Quarter 2016 Financial Results Download PDF
Valeant Pharmaceuticals Announces Significant Support For Education And Research Regarding Wilson Disease Date 08/08/16 Title Valeant Pharmaceuticals Announces Significant Support For Education And Research Regarding Wilson Disease Download PDF
Valeant Pharmaceuticals Announces Relaunch Of Generic Ofloxacin Otic Solution Date 08/08/16 Title Valeant Pharmaceuticals Announces Relaunch Of Generic Ofloxacin Otic Solution Download PDF
Valeant Pharmaceuticals Announces Licensing Agreement With Norgine B.V. For NER1006 In U.S. And Canada Date 08/08/16 Title Valeant Pharmaceuticals Announces Licensing Agreement With Norgine B.V. For NER1006 In U.S. And Canada Download PDF
Valeant Pharmaceuticals Announces Changes To Executive Management Team Date 08/08/16 Title Valeant Pharmaceuticals Announces Changes To Executive Management Team Download PDF
Valeant Pharmaceuticals Announces The Addition Of Sarah B. Kavanagh To Its Board Of Directors Date 07/28/16 Title Valeant Pharmaceuticals Announces The Addition Of Sarah B. Kavanagh To Its Board Of Directors Download PDF
Valeant Pharmaceuticals Receives Complete Response Letter From The FDA Date 07/22/16 Title Valeant Pharmaceuticals Receives Complete Response Letter From The FDA Download PDF
Valeant and Progenics Announce FDA Approves RELISTOR® Tablets for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-cancer Pain Date 07/19/16 Title Valeant and Progenics Announce FDA Approves RELISTOR® Tablets for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-cancer Pain Download PDF
FDA Advisory Committee Recommends Approval Of Brodalumab For Treatment Of Moderate-To-Severe Plaque Psoriasis Date 07/19/16 Title FDA Advisory Committee Recommends Approval Of Brodalumab For Treatment Of Moderate-To-Severe Plaque Psoriasis Download PDF
Valeant Pharmaceuticals Announces Second Quarter Results Conference Call Date And Details Date 07/15/16 Title Valeant Pharmaceuticals Announces Second Quarter Results Conference Call Date And Details Download PDF
Valeant Pharmaceuticals Comments On Recent Stock Transactions Date 07/14/16 Title Valeant Pharmaceuticals Comments On Recent Stock Transactions Download PDF
Bausch + Lomb and Nicox Announce the Publication of Latanoprostene Bunod Ophthalmic Solution 0.024% Phase 3 Study Results in American Journal of Ophthalmology Date 07/06/16 Title Bausch + Lomb and Nicox Announce the Publication of Latanoprostene Bunod Ophthalmic Solution 0.024% Phase 3 Study Results in American Journal of Ophthalmology Download PDF
Valeant Pharmaceuticals Announces New Licensing Arrangement For Brodalumab In Europe Date 07/01/16 Title Valeant Pharmaceuticals Announces New Licensing Arrangement For Brodalumab In Europe Download PDF
Canadian Shopper Study Names Bausch + Lomb Most Trusted Brand For Contact Lens Care Date 06/27/16 Title Canadian Shopper Study Names Bausch + Lomb Most Trusted Brand For Contact Lens Care Download PDF
Valeant Pharmaceuticals Announces Significant Investments In Canadian Operations Date 06/17/16 Title Valeant Pharmaceuticals Announces Significant Investments In Canadian Operations Download PDF
Valeant Pharmaceuticals Announces Launch Of New PreserVision® AREDS 2 Formula + Multivitamin Date 06/16/16 Title Valeant Pharmaceuticals Announces Launch Of New PreserVision® AREDS 2 Formula + Multivitamin Download PDF
Valeant Pharmaceuticals Appoints Thomas W. Ross, Sr. Lead Independent Director Date 06/15/16 Title Valeant Pharmaceuticals Appoints Thomas W. Ross, Sr. Lead Independent Director Download PDF
Valeant To Participate In FDA Advisory Committee Meeting On July 19 Date 06/09/16 Title Valeant To Participate In FDA Advisory Committee Meeting On July 19 Download PDF
Valeant Pharmaceuticals To Webcast 2016 Annual Meeting Of Shareholders Date 06/07/16 Title Valeant Pharmaceuticals To Webcast 2016 Annual Meeting Of Shareholders Download PDF
Valeant Pharmaceuticals Reports First Quarter 2016 Financial Results Date 06/07/16 Title Valeant Pharmaceuticals Reports First Quarter 2016 Financial Results Download PDF
Valeant Pharmaceuticals Receives Additional Notice Of Default Under Indentures Due To Delayed Form 10-Q Filing Date 06/03/16 Title Valeant Pharmaceuticals Receives Additional Notice Of Default Under Indentures Due To Delayed Form 10-Q Filing Download PDF
Valeant Pharmaceuticals To Present Six Abstracts At 2016 ASCO Annual Meeting Date 06/01/16 Title Valeant Pharmaceuticals To Present Six Abstracts At 2016 ASCO Annual Meeting Download PDF
Valeant Pharmaceuticals To Hold Conference Call On June 7, 2016 Date 05/31/16 Title Valeant Pharmaceuticals To Hold Conference Call On June 7, 2016 Download PDF
Valeant Pharmaceuticals Names Sam Eldessouky Senior Vice President And Corporate Controller Date 05/26/16 Title Valeant Pharmaceuticals Names Sam Eldessouky Senior Vice President And Corporate Controller Download PDF
Bausch + Lomb Wins Walmart "Supplier of the Year" Award Date 05/23/16 Title Bausch + Lomb Wins Walmart "Supplier of the Year" Award Download PDF
Valeant Pharmaceuticals Receives Notice Of Default From Bondholders Date 05/19/16 Title Valeant Pharmaceuticals Receives Notice Of Default From Bondholders Download PDF
Valeant Pharmaceuticals To Participate At The UBS Global Healthcare Conference Date 05/18/16 Title Valeant Pharmaceuticals To Participate At The UBS Global Healthcare Conference Download PDF
Valeant Pharmaceuticals Provides Update Regarding Regulatory Matters Date 05/16/16 Title Valeant Pharmaceuticals Provides Update Regarding Regulatory Matters Download PDF
Valeant Pharmaceuticals Announces Expanded Discounts For Nitropress And Isuprel Date 05/16/16 Title Valeant Pharmaceuticals Announces Expanded Discounts For Nitropress And Isuprel Download PDF
Valeant Pharmaceuticals Announces Expected Timing Of Form 10-Q Filing And Reiterates 2016 First Quarter Guidance Date 05/09/16 Title Valeant Pharmaceuticals Announces Expected Timing Of Form 10-Q Filing And Reiterates 2016 First Quarter Guidance Download PDF
Valeant Pharmaceuticals Announces Patient Access And Pricing Committee To Oversee Pricing Of Drugs Date 05/05/16 Title Valeant Pharmaceuticals Announces Patient Access And Pricing Committee To Oversee Pricing Of Drugs Download PDF
Valeant Pharmaceuticals Announces Collaboration Between Bausch + Lomb And IBM Date 05/05/16 Title Valeant Pharmaceuticals Announces Collaboration Between Bausch + Lomb And IBM Download PDF
Joseph C. Papa Assumes Role Of Chairman And Chief Executive Officer Of Valeant Pharmaceuticals Date 05/03/16 Title Joseph C. Papa Assumes Role Of Chairman And Chief Executive Officer Of Valeant Pharmaceuticals Download PDF
Valeant Announces Nominees For Election To Board Of Directors Date 04/29/16 Title Valeant Announces Nominees For Election To Board Of Directors Download PDF
Valeant Pharmaceuticals Files Annual Report On Form 10-K For Year Ended December 31, 2015 Date 04/29/16 Title Valeant Pharmaceuticals Files Annual Report On Form 10-K For Year Ended December 31, 2015 Download PDF
Valeant Names Joseph C. Papa To Be Chairman And Chief Executive Officer Of Valeant Pharmaceuticals Date 04/25/16 Title Valeant Names Joseph C. Papa To Be Chairman And Chief Executive Officer Of Valeant Pharmaceuticals Download PDF
Valeant Pharmaceuticals Receives Additional Notices Of Default Under Indentures Due To Delayed 10-K Filing Date 04/22/16 Title Valeant Pharmaceuticals Receives Additional Notices Of Default Under Indentures Due To Delayed 10-K Filing Download PDF
Valeant Pharmaceuticals Provides Update Regarding Regulatory Matters Date 04/13/16 Title Valeant Pharmaceuticals Provides Update Regarding Regulatory Matters Download PDF
Valeant Pharmaceuticals Receives Notice Of Default From Bondholders Due To Delayed 10-K Filing Date 04/12/16 Title Valeant Pharmaceuticals Receives Notice Of Default From Bondholders Due To Delayed 10-K Filing Download PDF
Valeant Board Of Directors Issues Statement On J. Michael Pearson's Cooperation With Senate Committee on Aging Date 04/11/16 Title Valeant Board Of Directors Issues Statement On J. Michael Pearson's Cooperation With Senate Committee on Aging Download PDF
Valeant Pharmaceuticals Receives Lender Consent For Credit Facility Amendment Date 04/07/16 Title Valeant Pharmaceuticals Receives Lender Consent For Credit Facility Amendment Download PDF
Valeant Ad Hoc Committee Announces Completion Of Its Review Of Philidor And Related Accounting Matters Date 04/05/16 Title Valeant Ad Hoc Committee Announces Completion Of Its Review Of Philidor And Related Accounting Matters Download PDF
Valeant and Progenics Announce PDUFA Date Extension for Oral RELISTOR Date 04/04/16 Title Valeant and Progenics Announce PDUFA Date Extension for Oral RELISTOR Download PDF
Valeant Pharmaceuticals Launches Credit Facility Amendment Date 03/30/16 Title Valeant Pharmaceuticals Launches Credit Facility Amendment Download PDF
Valeant Announces CEO Succession Plan And Changes To Board Of Directors; Provides Accounting And Financial Reporting Update Date 03/21/16 Title Valeant Announces CEO Succession Plan And Changes To Board Of Directors; Provides Accounting And Financial Reporting Update Download PDF
/C O R R E C T I O N -- Valeant Pharmaceuticals International, Inc./ Date 03/15/16 Title /C O R R E C T I O N -- Valeant Pharmaceuticals International, Inc./ Download PDF
Valeant And R&O Pharmacy End Litigation Date 03/09/16 Title Valeant And R&O Pharmacy End Litigation Download PDF
Valeant Pharmaceuticals Announces The Addition Of Three New Independent Directors To Its Board Date 03/09/16 Title Valeant Pharmaceuticals Announces The Addition Of Three New Independent Directors To Its Board Download PDF
Valeant Pharmaceuticals To Hold Conference Call On March 15, 2016 Date 03/07/16 Title Valeant Pharmaceuticals To Hold Conference Call On March 15, 2016 Download PDF
Valeant Pharmaceuticals Comments On Management Change Date 03/03/16 Title Valeant Pharmaceuticals Comments On Management Change Download PDF
Valeant Pharmaceuticals Announces Management Change Date 03/02/16 Title Valeant Pharmaceuticals Announces Management Change Download PDF
Valeant Pharmaceuticals Announces Management And Business Update Date 02/28/16 Title Valeant Pharmaceuticals Announces Management And Business Update Download PDF
Valeant Ad Hoc Committee has Made Substantial Progress in Its Review of Philidor and Related Accounting Matters Date 02/22/16 Title Valeant Ad Hoc Committee has Made Substantial Progress in Its Review of Philidor and Related Accounting Matters Download PDF
Valeant Announces FDA Acceptance of BLA Submission for Brodalumab in Moderate-to-Severe Plaque Psoriasis Date 01/25/16 Title Valeant Announces FDA Acceptance of BLA Submission for Brodalumab in Moderate-to-Severe Plaque Psoriasis Download PDF
Valeant Provides Update On J. Michael Pearson Date 01/25/16 Title Valeant Provides Update On J. Michael Pearson Download PDF
Valeant Names Howard B. Schiller Interim CEO Date 01/06/16 Title Valeant Names Howard B. Schiller Interim CEO Download PDF
Valeant Pharmaceuticals To Present At The 34th Annual J.P. Morgan Healthcare Conference Date 01/04/16 Title Valeant Pharmaceuticals To Present At The 34th Annual J.P. Morgan Healthcare Conference Download PDF
Valeant Announces J. Michael Pearson Will Be On Medical Leave of Absence Date 12/28/15 Title Valeant Announces J. Michael Pearson Will Be On Medical Leave of Absence Download PDF
Valeant Provides Financial Guidance Update Date 12/16/15 Title Valeant Provides Financial Guidance Update Download PDF
Valeant Announces New U.S. Fulfillment Agreements With Walgreens; Plans To Further Extend Distribution To Independent Pharmacies Date 12/15/15 Title Valeant Announces New U.S. Fulfillment Agreements With Walgreens; Plans To Further Extend Distribution To Independent Pharmacies Download PDF
Valeant To Hold Investor Day On December 16 (Updated) Date 11/20/15 Title Valeant To Hold Investor Day On December 16 (Updated) Download PDF
Valeant Pharmaceuticals To Present At Industry Conference Date 11/12/15 Title Valeant Pharmaceuticals To Present At Industry Conference Download PDF
Valeant To Hold Conference Call For Investors To Provide Business Update Date 11/09/15 Title Valeant To Hold Conference Call For Investors To Provide Business Update Download PDF
Valeant Issues Statement On Sales Of Company Stock Date 11/06/15 Title Valeant Issues Statement On Sales Of Company Stock Download PDF
Former Deputy Attorney General Appointed To Advise Valeant's Ad Hoc Committee Date 10/30/15 Title Former Deputy Attorney General Appointed To Advise Valeant's Ad Hoc Committee Download PDF
Valeant To Terminate Relationship With Philidor Date 10/30/15 Title Valeant To Terminate Relationship With Philidor Download PDF
Statements Of J. Michael Pearson, Chairman And CEO, And Robert Ingram, Lead Outside Director Of Valeant Pharmaceuticals Date 10/26/15 Title Statements Of J. Michael Pearson, Chairman And CEO, And Robert Ingram, Lead Outside Director Of Valeant Pharmaceuticals Download PDF
Valeant Pharmaceuticals Confirms Appropriateness Of Accounting, Appoints Ad Hoc Board Committee To Review Philidor Date 10/26/15 Title Valeant Pharmaceuticals Confirms Appropriateness Of Accounting, Appoints Ad Hoc Board Committee To Review Philidor Download PDF
Valeant Pharmaceuticals Announces The Addition Of G. Mason Morfit To Its Board Of Directors Date 10/26/15 Title Valeant Pharmaceuticals Announces The Addition Of G. Mason Morfit To Its Board Of Directors Download PDF
Valeant Pharmaceuticals To Hold Investor Conference Call On October 26, 2015 Date 10/22/15 Title Valeant Pharmaceuticals To Hold Investor Conference Call On October 26, 2015 Download PDF
Valeant Pharmaceuticals Responds To Erroneous Report Date 10/21/15 Title Valeant Pharmaceuticals Responds To Erroneous Report Download PDF
Valeant Pharmaceuticals Reports Third Quarter 2015 Financial Results Date 10/19/15 Title Valeant Pharmaceuticals Reports Third Quarter 2015 Financial Results Download PDF
Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Synergetics USA, Inc. Date 10/15/15 Title Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Synergetics USA, Inc. Download PDF
Valeant Pharmaceuticals International, Inc. Completes Tender Offer For Synergetics USA, Inc. Date 10/15/15 Title Valeant Pharmaceuticals International, Inc. Completes Tender Offer For Synergetics USA, Inc. Download PDF
Valeant Provides Update Regarding Government Inquiries Date 10/14/15 Title Valeant Provides Update Regarding Government Inquiries Download PDF
Valeant Pharmaceuticals Celebrates the Manufacturing of Four Billion Bottles of Eye Care Products at Bausch + Lomb's Greenville Solutions Plant Date 10/13/15 Title Valeant Pharmaceuticals Celebrates the Manufacturing of Four Billion Bottles of Eye Care Products at Bausch + Lomb's Greenville Solutions Plant Download PDF
Valeant Pharmaceuticals To Announce 2015 Third Quarter Results On October 19, 2015 Date 10/05/15 Title Valeant Pharmaceuticals To Announce 2015 Third Quarter Results On October 19, 2015 Download PDF
Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Synergetics USA, Inc. Date 10/05/15 Title Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Synergetics USA, Inc. Download PDF
Bausch + Lomb and Nicox Announce FDA Acceptance of New Drug Application for Novel Glaucoma Candidate VESNEO™ (latanoprostene bunod) Date 09/22/15 Title Bausch + Lomb and Nicox Announce FDA Acceptance of New Drug Application for Novel Glaucoma Candidate VESNEO™ (latanoprostene bunod) Download PDF
Valeant And Progenics Announce FDA Acceptance Of NDA Submission For Oral RELISTOR® Date 09/08/15 Title Valeant And Progenics Announce FDA Acceptance Of NDA Submission For Oral RELISTOR® Download PDF
Valeant Pharmaceuticals To Acquire Synergetics USA Date 09/02/15 Title Valeant Pharmaceuticals To Acquire Synergetics USA Download PDF
Valeant And AstraZeneca To Partner On Brodalumab Date 09/01/15 Title Valeant And AstraZeneca To Partner On Brodalumab Download PDF
Valeant Pharmaceuticals Announces The Addition Of D. Robert Hale To Its Board Of Directors Date 08/25/15 Title Valeant Pharmaceuticals Announces The Addition Of D. Robert Hale To Its Board Of Directors Download PDF
Valeant Pharmaceuticals To Acquire Sprout Pharmaceuticals Date 08/20/15 Title Valeant Pharmaceuticals To Acquire Sprout Pharmaceuticals Download PDF
Valeant Pharmaceuticals Reports Second Quarter 2015 Financial Results Date 07/23/15 Title Valeant Pharmaceuticals Reports Second Quarter 2015 Financial Results Download PDF
Valeant Pharmaceuticals Agrees To Acquire Amoun Pharmaceutical Date 07/17/15 Title Valeant Pharmaceuticals Agrees To Acquire Amoun Pharmaceutical Download PDF
Valeant Pharmaceuticals To Announce 2015 Second Quarter Results On July 23, 2015 Date 06/24/15 Title Valeant Pharmaceuticals To Announce 2015 Second Quarter Results On July 23, 2015 Download PDF
Valeant and Progenics Announce the Submission of U.S. New Drug Application for Oral RELISTOR® Date 06/23/15 Title Valeant and Progenics Announce the Submission of U.S. New Drug Application for Oral RELISTOR® Download PDF
Valeant Pharmaceuticals To Appoint Robert L. Rosiello As Chief Financial Officer Date 06/11/15 Title Valeant Pharmaceuticals To Appoint Robert L. Rosiello As Chief Financial Officer Download PDF
Salix Announces FDA Approval of Xifaxan® 550 mg for the Treatment of IBS-D (Irritable Bowel Syndrome with Diarrhea) Date 05/27/15 Title Salix Announces FDA Approval of Xifaxan® 550 mg for the Treatment of IBS-D (Irritable Bowel Syndrome with Diarrhea) Download PDF
Valeant Pharmaceuticals Announces 2015 Annual Meeting Results Date 05/19/15 Title Valeant Pharmaceuticals Announces 2015 Annual Meeting Results Download PDF
Valeant Pharmaceuticals To Webcast 2015 Annual Meeting Of Shareholders Date 05/12/15 Title Valeant Pharmaceuticals To Webcast 2015 Annual Meeting Of Shareholders Download PDF
Valeant Pharmaceuticals Reports First Quarter 2015 Financial Results (PDF Version) Date 04/29/15 Title Valeant Pharmaceuticals Reports First Quarter 2015 Financial Results (PDF Version) Download PDF
Valeant Pharmaceuticals Reports First Quarter 2015 Financial Results Date 04/29/15 Title Valeant Pharmaceuticals Reports First Quarter 2015 Financial Results Download PDF
Valeant Announces CFO Succession Plan And Additional Executive Appointment Date 04/29/15 Title Valeant Announces CFO Succession Plan And Additional Executive Appointment Download PDF
RELISTOR® Receives Positive CHMP Opinion in the EU for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain Date 04/24/15 Title RELISTOR® Receives Positive CHMP Opinion in the EU for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain Download PDF
Valeant Pharmaceuticals To Announce 2015 First Quarter Results On April 29, 2015 Date 04/09/15 Title Valeant Pharmaceuticals To Announce 2015 First Quarter Results On April 29, 2015 Download PDF
Salix Provides Notice of Fundamental Changes, Make-Whole Fundamental Changes and Merger Event Relating to Its 2.75% Convertible Senior Notes Due 2015 Date 04/01/15 Title Salix Provides Notice of Fundamental Changes, Make-Whole Fundamental Changes and Merger Event Relating to Its 2.75% Convertible Senior Notes Due 2015 Download PDF
Salix Provides Notice of Fundamental Changes, Make-Whole Fundamental Changes and Merger Event Relating to Its 1.5% Convertible Senior Notes Due 2019 Date 04/01/15 Title Salix Provides Notice of Fundamental Changes, Make-Whole Fundamental Changes and Merger Event Relating to Its 1.5% Convertible Senior Notes Due 2019 Download PDF
Redemption of All of Salix's Outstanding 6.00% Senior Notes due 2021 Date 04/01/15 Title Redemption of All of Salix's Outstanding 6.00% Senior Notes due 2021 Download PDF
Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Salix Pharmaceuticals Date 04/01/15 Title Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Salix Pharmaceuticals Download PDF
Valeant Pharmaceuticals International, Inc. Completes Tender Offer For Salix Pharmaceuticals, Ltd. Date 04/01/15 Title Valeant Pharmaceuticals International, Inc. Completes Tender Offer For Salix Pharmaceuticals, Ltd. Download PDF
Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares Date 03/27/15 Title Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares Download PDF
Valeant Pharmaceuticals Prices Offering Of $1.45 Billion Of Common Shares Date 03/17/15 Title Valeant Pharmaceuticals Prices Offering Of $1.45 Billion Of Common Shares Download PDF
Valeant Pharmaceuticals Announces Offering Of $1.45 Billion Of Common Shares Date 03/16/15 Title Valeant Pharmaceuticals Announces Offering Of $1.45 Billion Of Common Shares Download PDF
Valeant And Salix Agree On Amended Terms To Merger Agreement Date 03/16/15 Title Valeant And Salix Agree On Amended Terms To Merger Agreement Download PDF
Valeant Announces HSR Clearance For Salix Acquisition Date 03/13/15 Title Valeant Announces HSR Clearance For Salix Acquisition Download PDF
Valeant Announces Pricing Of Private Offering Of Senior Notes Date 03/13/15 Title Valeant Announces Pricing Of Private Offering Of Senior Notes Download PDF
Valeant Comments On Endo Offer To Acquire Salix Date 03/11/15 Title Valeant Comments On Endo Offer To Acquire Salix Download PDF
Valeant Announces Launch Of Private Offering Of Senior Notes Date 03/09/15 Title Valeant Announces Launch Of Private Offering Of Senior Notes Download PDF
PROVENGE® (sipuleucel-T) Demonstrates Sustained Immune Response Two Years after Treatment in Biochemically-Recurrent Prostate Cancer Date 02/25/15 Title PROVENGE® (sipuleucel-T) Demonstrates Sustained Immune Response Two Years after Treatment in Biochemically-Recurrent Prostate Cancer Download PDF
Valeant To Acquire Salix Pharmaceuticals For $158.00 Per Share In Cash Date 02/22/15 Title Valeant To Acquire Salix Pharmaceuticals For $158.00 Per Share In Cash Download PDF
Valeant Pharmaceuticals Reports Fourth Quarter And Full Year 2014 Financial Results Date 02/22/15 Title Valeant Pharmaceuticals Reports Fourth Quarter And Full Year 2014 Financial Results Download PDF
Valeant Pharmaceuticals Announces Expiration Of Bid Deadline In Connection With Agreement To Acquire Assets From Dendreon Date 02/10/15 Title Valeant Pharmaceuticals Announces Expiration Of Bid Deadline In Connection With Agreement To Acquire Assets From Dendreon Download PDF
Valeant Enters Into Amended Agreement To Remain Lead Bidder In Acquisition Of Dendreon And Its Leading Immunotherapy Treatment, PROVENGE® (sipuleucel-T) Date 02/05/15 Title Valeant Enters Into Amended Agreement To Remain Lead Bidder In Acquisition Of Dendreon And Its Leading Immunotherapy Treatment, PROVENGE® (sipuleucel-T) Download PDF
Valeant Pharmaceuticals To Announce 2014 Fourth Quarter And Full Year Results On February 24, 2015 Date 02/05/15 Title Valeant Pharmaceuticals To Announce 2014 Fourth Quarter And Full Year Results On February 24, 2015 Download PDF
Valeant Selected As Lead Bidder To Acquire Dendreon And Its Leading Immunotherapy Treatment, PROVENGE® (sipuleucel-T) Date 01/29/15 Title Valeant Selected As Lead Bidder To Acquire Dendreon And Its Leading Immunotherapy Treatment, PROVENGE® (sipuleucel-T) Download PDF
Bausch + Lomb Introduces New Software and Advanced OCT Imaging System for VICTUS® Femtosecond Laser Platform Date 01/20/15 Title Bausch + Lomb Introduces New Software and Advanced OCT Imaging System for VICTUS® Femtosecond Laser Platform Download PDF
Valeant Announces Redemption of All of the Approximately $500 Million Aggregate Principal Amount of its Outstanding 6.875% Senior Notes due 2018 Date 01/15/15 Title Valeant Announces Redemption of All of the Approximately $500 Million Aggregate Principal Amount of its Outstanding 6.875% Senior Notes due 2018 Download PDF
Valeant Announces Pricing Of Private Offering Of Senior Notes Date 01/15/15 Title Valeant Announces Pricing Of Private Offering Of Senior Notes Download PDF
Valeant Announces Launch of Private Offering of Senior Notes Date 01/15/15 Title Valeant Announces Launch of Private Offering of Senior Notes Download PDF
Valeant Pharmaceuticals To Present At The J.P. Morgan 2015 Healthcare Conference Date 01/06/15 Title Valeant Pharmaceuticals To Present At The J.P. Morgan 2015 Healthcare Conference Download PDF
Valeant Pharmaceuticals To Hold Conference Call To Announce 2015 Financial Guidance Date 12/15/14 Title Valeant Pharmaceuticals To Hold Conference Call To Announce 2015 Financial Guidance Download PDF
Valeant Announces Redemption of US$445.0 Million Aggregate Principal Amount of its Outstanding 6.875% Senior Notes due 2018 Date 11/28/14 Title Valeant Announces Redemption of US$445.0 Million Aggregate Principal Amount of its Outstanding 6.875% Senior Notes due 2018 Download PDF
Valeant Pharmaceuticals Announces FDA Approval Of ONEXTON™ Gel For The Treatment Of Acne Vulgaris Date 11/25/14 Title Valeant Pharmaceuticals Announces FDA Approval Of ONEXTON™ Gel For The Treatment Of Acne Vulgaris Download PDF
Valeant Pharmaceuticals Announces New $2 Billion Securities Repurchase Program Date 11/20/14 Title Valeant Pharmaceuticals Announces New $2 Billion Securities Repurchase Program Download PDF
Valeant Comments On Allergan Announcement Date 11/17/14 Title Valeant Comments On Allergan Announcement Download PDF
Valeant Pharmaceuticals Completes Renovation Of U.S. Headquarters In New Jersey Date 11/13/14 Title Valeant Pharmaceuticals Completes Renovation Of U.S. Headquarters In New Jersey Download PDF
Valeant Pharmaceuticals Sends Letter To Physician Customers Date 11/07/14 Title Valeant Pharmaceuticals Sends Letter To Physician Customers Download PDF
Valeant And Pershing Square May Vote At Special Meeting Date 11/04/14 Title Valeant And Pershing Square May Vote At Special Meeting Download PDF
Valeant Delivers Letter To Allergan Board Date 10/27/14 Title Valeant Delivers Letter To Allergan Board Download PDF
Valeant Pharmaceuticals Reports Third Quarter 2014 Financial Results Date 10/20/14 Title Valeant Pharmaceuticals Reports Third Quarter 2014 Financial Results Download PDF
Valeant Pharmaceuticals To Announce 2014 Third Quarter Results On October 20, 2014 Date 10/15/14 Title Valeant Pharmaceuticals To Announce 2014 Third Quarter Results On October 20, 2014 Download PDF
Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA Date 09/30/14 Title Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA Download PDF
Bausch + Lomb Announces Successful Results from Phase 3 Study of Sub-Micron Loteprednol Etabonate Ophthalmic Gel, 0.38% Date 09/26/14 Title Bausch + Lomb Announces Successful Results from Phase 3 Study of Sub-Micron Loteprednol Etabonate Ophthalmic Gel, 0.38% Download PDF
Jeffrey W. Ubben, CEO Of ValueAct Capital, Appointed To The Board Of Valeant Pharmaceuticals Date 09/25/14 Title Jeffrey W. Ubben, CEO Of ValueAct Capital, Appointed To The Board Of Valeant Pharmaceuticals Download PDF
Bausch + Lomb and Nicox's Glaucoma Candidate VESNEO™ (latanoprostene bunod) Meets Primary Endpoint in Phase 3 Studies Date 09/25/14 Title Bausch + Lomb and Nicox's Glaucoma Candidate VESNEO™ (latanoprostene bunod) Meets Primary Endpoint in Phase 3 Studies Download PDF
Valeant Provides Update On Third Quarter Results And Sends Letter To Allergan CEO And Lead Independent Director Date 09/24/14 Title Valeant Provides Update On Third Quarter Results And Sends Letter To Allergan CEO And Lead Independent Director Download PDF
Valeant Announces Redemption of All of the Outstanding $500.0 Million Aggregate Principal Amount of its 6.75% Senior Notes due 2017 Date 09/15/14 Title Valeant Announces Redemption of All of the Outstanding $500.0 Million Aggregate Principal Amount of its 6.75% Senior Notes due 2017 Download PDF
Valeant Pharmaceuticals Expands Bausch + Lomb Manufacturing Facility, Adding 120 New Jobs in Rochester Date 09/08/14 Title Valeant Pharmaceuticals Expands Bausch + Lomb Manufacturing Facility, Adding 120 New Jobs in Rochester Download PDF
Valeant Extends Offer To Acquire Allergan Date 08/15/14 Title Valeant Extends Offer To Acquire Allergan Download PDF
Valeant Pharmaceuticals Receives FTC Second Request Under Hart-Scott-Rodino Date 08/11/14 Title Valeant Pharmaceuticals Receives FTC Second Request Under Hart-Scott-Rodino Download PDF
Institutional Shareholder Services (ISS) Recommends Allergan Shareholders Call A Special Meeting Of Shareholders Date 08/06/14 Title Institutional Shareholder Services (ISS) Recommends Allergan Shareholders Call A Special Meeting Of Shareholders Download PDF
Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit Date 08/01/14 Title Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit Download PDF
Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results Date 07/31/14 Title Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results Download PDF
Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results (pdf version) Date 07/31/14 Title Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results (pdf version) Download pdf
Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements Date 07/24/14 Title Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements Download PDF
Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements Date 07/21/14 Title Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements Download PDF
Valeant Pharmaceuticals Files Investor Presentation Date 07/18/14 Title Valeant Pharmaceuticals Files Investor Presentation Download PDF
Bausch + Lomb's VICTUS® Femtosecond Laser Platform Receives 510(k) Clearance from FDA for Lens Fragmentation Procedure Date 07/17/14 Title Bausch + Lomb's VICTUS® Femtosecond Laser Platform Receives 510(k) Clearance from FDA for Lens Fragmentation Procedure Download PDF
Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan Date 07/14/14 Title Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan Download PDF
Valeant Pharmaceuticals Completes Sale Of Filler And Toxin Assets To Galderma Date 07/10/14 Title Valeant Pharmaceuticals Completes Sale Of Filler And Toxin Assets To Galderma Download PDF
Valeant Pharmaceuticals Completes Acquisition Of PreCision Dermatology Date 07/08/14 Title Valeant Pharmaceuticals Completes Acquisition Of PreCision Dermatology Download PDF
Valeant Files Preliminary Proxy Statement for Special Meeting of Shareholders to Approve Share Issuance in Proposed Acquisition of Allergan Date 06/25/14 Title Valeant Files Preliminary Proxy Statement for Special Meeting of Shareholders to Approve Share Issuance in Proposed Acquisition of Allergan Download PDF
Valeant Posts Fact-Based Answers To Refute Allergan's Misleading Statements Date 06/23/14 Title Valeant Posts Fact-Based Answers To Refute Allergan's Misleading Statements Download PDF
Valeant Commences Exchange Offer For Allergan Date 06/18/14 Title Valeant Commences Exchange Offer For Allergan Download PDF
Valeant Pharmaceuticals Receives U.S. FDA Clearance For Restylane® Silk Date 06/16/14 Title Valeant Pharmaceuticals Receives U.S. FDA Clearance For Restylane® Silk Download PDF
Valeant Pharmaceuticals Announces Planned Management Departure Date 06/13/14 Title Valeant Pharmaceuticals Announces Planned Management Departure Download PDF
Valeant Pharmaceuticals To Hold Conference Call On Tuesday, June 17, 2014 To Correct Recent Misrepresentations Date 06/13/14 Title Valeant Pharmaceuticals To Hold Conference Call On Tuesday, June 17, 2014 To Correct Recent Misrepresentations Download PDF
Valeant Pharmaceuticals Announces FDA Approval Of Jublia® for the Treatment of Onychomycosis Date 06/09/14 Title Valeant Pharmaceuticals Announces FDA Approval Of Jublia® for the Treatment of Onychomycosis Download PDF
Valeant And Pershing Square Make Revised Offer For Allergan Contingent On Good Faith Negotiations Date 05/30/14 Title Valeant And Pershing Square Make Revised Offer For Allergan Contingent On Good Faith Negotiations Download PDF
Valeant Substantially Increases Merger Proposal For Allergan Date 05/28/14 Title Valeant Substantially Increases Merger Proposal For Allergan Download PDF
Valeant Pharmaceuticals To Sell Filler And Toxin Assets To Nestle For $1.4 Billion Date 05/28/14 Title Valeant Pharmaceuticals To Sell Filler And Toxin Assets To Nestle For $1.4 Billion Download PDF
Valeant To Host In-Person Investor Meeting And Webcast On May 28, 2014 At 8:00 A.M. ET Date 05/27/14 Title Valeant To Host In-Person Investor Meeting And Webcast On May 28, 2014 At 8:00 A.M. ET Download PDF
Valeant Pharmaceuticals to Present at the Sanford C. Bernstein Thirtieth Annual Strategic Decisions Conference 2014 Date 05/23/14 Title Valeant Pharmaceuticals to Present at the Sanford C. Bernstein Thirtieth Annual Strategic Decisions Conference 2014 Download PDF
Valeant Pharmaceuticals Announces 2014 Annual Meeting Results Date 05/21/14 Title Valeant Pharmaceuticals Announces 2014 Annual Meeting Results Download PDF
Valeant to Discuss Allergan Proposal at Investor Meeting and Webcast on May 28, 2014 at 8:00 A.M. ET Date 05/20/14 Title Valeant to Discuss Allergan Proposal at Investor Meeting and Webcast on May 28, 2014 at 8:00 A.M. ET Download PDF
Valeant Pharmaceuticals Responds to Allergan's Rejection of Merger Proposal Date 05/13/14 Title Valeant Pharmaceuticals Responds to Allergan's Rejection of Merger Proposal Download PDF
Valeant Pharmaceuticals Enters Into Patent Settlement Agreements With Actavis Date 05/12/14 Title Valeant Pharmaceuticals Enters Into Patent Settlement Agreements With Actavis Download PDF
Valeant Pharmaceuticals Reports First Quarter 2014 Financial Results Date 05/08/14 Title Valeant Pharmaceuticals Reports First Quarter 2014 Financial Results Download PDF
Valeant Pharmaceuticals To Webcast 2014 Annual Meeting Of Shareholders Date 05/01/14 Title Valeant Pharmaceuticals To Webcast 2014 Annual Meeting Of Shareholders Download PDF
Valeant And Pershing Square Investor Meeting Webcast Replay And Presentations Now Available Date 04/24/14 Title Valeant And Pershing Square Investor Meeting Webcast Replay And Presentations Now Available Download PDF
Valeant Pharmaceuticals To Announce 2014 First Quarter Results On May 8, 2014 Date 04/24/14 Title Valeant Pharmaceuticals To Announce 2014 First Quarter Results On May 8, 2014 Download PDF
Valeant Pharmaceuticals Announces Nominations For Board Of Directors Date 04/23/14 Title Valeant Pharmaceuticals Announces Nominations For Board Of Directors Download PDF
Valeant Proposes to Combine With Allergan for $48.30 in Cash and 0.83 Shares of Valeant Stock for Each Allergan Share Date 04/22/14 Title Valeant Proposes to Combine With Allergan for $48.30 in Cash and 0.83 Shares of Valeant Stock for Each Allergan Share Download PDF
Actavis and Valeant Announce FDA Approval for Metronidazole 1.3% Date 03/25/14 Title Actavis and Valeant Announce FDA Approval for Metronidazole 1.3% Download PDF
Valeant Pharmaceuticals Reports Fourth Quarter And Full Year 2013 Financial Results Date 02/27/14 Title Valeant Pharmaceuticals Reports Fourth Quarter And Full Year 2013 Financial Results Download PDF
Valeant Pharmaceuticals To Announce 2013 Fourth Quarter And Full Year Results On February 27, 2014 Date 02/05/14 Title Valeant Pharmaceuticals To Announce 2013 Fourth Quarter And Full Year Results On February 27, 2014 Download PDF
Valeant Pharmaceuticals to Acquire Precision Dermatology for $475 Million Date 02/03/14 Title Valeant Pharmaceuticals to Acquire Precision Dermatology for $475 Million Download PDF
Valeant Pharmaceuticals Announces Approval of Retin-A Micro® Microsphere 0.08% Date 01/31/14 Title Valeant Pharmaceuticals Announces Approval of Retin-A Micro® Microsphere 0.08% Download PDF
Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Solta Medical, Inc. Date 01/23/14 Title Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Solta Medical, Inc. Download PDF
Valeant Pharmaceuticals International, Inc. Completes Tender Offer for Solta Medical, Inc. Date 01/23/14 Title Valeant Pharmaceuticals International, Inc. Completes Tender Offer for Solta Medical, Inc. Download PDF
Valeant Pharmaceuticals Announces New $1.5 Billion Securities Repurchase Program Date 01/22/14 Title Valeant Pharmaceuticals Announces New $1.5 Billion Securities Repurchase Program Download PDF
Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. Date 01/15/14 Title Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. Download PDF
Valeant Pharmaceuticals To Present At Industry Conferences Date 12/20/13 Title Valeant Pharmaceuticals To Present At Industry Conferences Download PDF
Valeant Pharmaceuticals Agrees to Acquire Solta Medical for $2.92 Per Share in Cash Date 12/16/13 Title Valeant Pharmaceuticals Agrees to Acquire Solta Medical for $2.92 Per Share in Cash Download PDF
Valeant Pharmaceuticals To Hold Conference Call To Announce 2014 Financial Guidance Date 12/13/13 Title Valeant Pharmaceuticals To Hold Conference Call To Announce 2014 Financial Guidance Download PDF
Valeant Pharmaceuticals Announces Redemption Of The Remaining $465.5 Million Aggrerate Principal Amount Of Its Outstanding 6.50% Senior Notes Due 2016 Date 12/02/13 Title Valeant Pharmaceuticals Announces Redemption Of The Remaining $465.5 Million Aggrerate Principal Amount Of Its Outstanding 6.50% Senior Notes Due 2016 Download PDF
Valeant Pharmaceuticals Announces New Management Appointment Date 11/25/13 Title Valeant Pharmaceuticals Announces New Management Appointment Download PDF
Valeant Pharmaceuticals Announces Pricing Of Private Offering Of Senior Notes Date 11/15/13 Title Valeant Pharmaceuticals Announces Pricing Of Private Offering Of Senior Notes Download PDF
Valeant Pharmaceuticals Announced Redemption Of $450 Million Aggregate Principal Amount Of Its Outstanding 6.50% Senior Notes Due 2016 Date 11/15/13 Title Valeant Pharmaceuticals Announced Redemption Of $450 Million Aggregate Principal Amount Of Its Outstanding 6.50% Senior Notes Due 2016 Download PDF
Valeant Pharmaceuticals Announces U.S. Approval Of Luzu® Cream, 1% Date 11/15/13 Title Valeant Pharmaceuticals Announces U.S. Approval Of Luzu® Cream, 1% Download PDF
Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes Date 11/15/13 Title Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes Download PDF
Valeant Pharmaceuticals Reports 2013 Third Quarter Financial Results Date 10/31/13 Title Valeant Pharmaceuticals Reports 2013 Third Quarter Financial Results Download PDF
Valeant Pharmaceuticals Announces Settlement Agreement With Anacor Date 10/28/13 Title Valeant Pharmaceuticals Announces Settlement Agreement With Anacor Download PDF
Valeant Pharmaceuticals Announces Award In Anacor Dispute Date 10/18/13 Title Valeant Pharmaceuticals Announces Award In Anacor Dispute Download PDF
Valeant Pharmaceuticals To Announce 2013 Third Quarter Results On October 31, 2013 Date 10/08/13 Title Valeant Pharmaceuticals To Announce 2013 Third Quarter Results On October 31, 2013 Download PDF
Valeant Pharmaceuticals Announces Approval Of Jublia® For The Treatment Of Onychomycosis In Canada Date 10/03/13 Title Valeant Pharmaceuticals Announces Approval Of Jublia® For The Treatment Of Onychomycosis In Canada Download PDF
Valeant Pharmaceuticals' Bausch + Lomb Receives U.S. FDA Clearance For Novel Monthly Disposable Contact Lens Date 10/03/13 Title Valeant Pharmaceuticals' Bausch + Lomb Receives U.S. FDA Clearance For Novel Monthly Disposable Contact Lens Download PDF
Valeant Pharmaceuticals Announces Partnership With National Coalition Against Domestic Violence Date 10/02/13 Title Valeant Pharmaceuticals Announces Partnership With National Coalition Against Domestic Violence Download PDF
Valeant Pharmaceuticals Announces Continuance Date 08/09/13 Title Valeant Pharmaceuticals Announces Continuance Download PDF
Valeant Pharmaceuticals Reports 2013 Second Quarter Financial Results Date 08/07/13 Title Valeant Pharmaceuticals Reports 2013 Second Quarter Financial Results Download PDF
Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Bausch + Lomb Date 08/06/13 Title Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Bausch + Lomb Download PDF
Valeant Pharmaceuticals To Announce 2013 Second Quarter Results On August 7, 2013 Date 07/15/13 Title Valeant Pharmaceuticals To Announce 2013 Second Quarter Results On August 7, 2013 Download PDF
Medicis Announces Five-Year Aesthetic Collaboration with Mentor Date 07/02/13 Title Medicis Announces Five-Year Aesthetic Collaboration with Mentor Download PDF
Valeant Pharmaceuticals Announces Pricing Of Private Offering Of Senior Notes Date 06/27/13 Title Valeant Pharmaceuticals Announces Pricing Of Private Offering Of Senior Notes Download PDF
Valeant Pharmaceuticals Announces Closing of Public Offering of Common Shares Date 06/24/13 Title Valeant Pharmaceuticals Announces Closing of Public Offering of Common Shares Download PDF
Valeant Pharmaceuticals Announces Exercise Of Over-Allotment Option Date 06/20/13 Title Valeant Pharmaceuticals Announces Exercise Of Over-Allotment Option Download PDF
Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes Date 06/18/13 Title Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes Download PDF
Valeant Pharmaceuticals Prices Public Offering Of Common Shares Date 06/18/13 Title Valeant Pharmaceuticals Prices Public Offering Of Common Shares Download PDF
Valeant Pharmaceuticals Announces Public Offering Of Common Shares Date 06/17/13 Title Valeant Pharmaceuticals Announces Public Offering Of Common Shares Download PDF
Valeant Pharmaceuticals Announces Filing Of Preliminary Base Shelf Prospectus Date 06/07/13 Title Valeant Pharmaceuticals Announces Filing Of Preliminary Base Shelf Prospectus Download PDF
Valeant Pharmaceuticals Announces Receipt Of U.S. FDA Complete Response Letter For Efinaconazole Date 05/28/13 Title Valeant Pharmaceuticals Announces Receipt Of U.S. FDA Complete Response Letter For Efinaconazole Download PDF
Valeant Pharmaceuticals International, Inc. To Acquire Bausch + Lomb For $8.7 Billion Date 05/27/13 Title Valeant Pharmaceuticals International, Inc. To Acquire Bausch + Lomb For $8.7 Billion Download PDF
Valeant Pharmaceuticals Announces 2013 Annual Meeting Results Date 05/21/13 Title Valeant Pharmaceuticals Announces 2013 Annual Meeting Results Download PDF
Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference Date 05/20/13 Title Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference Download PDF
Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeant's Board of Directors Date 05/15/13 Title Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeant's Board of Directors Download PDF
Valeant Pharmaceuticals To Webcast 2013 Annual Meeting Of Shareholders Date 05/13/13 Title Valeant Pharmaceuticals To Webcast 2013 Annual Meeting Of Shareholders Download PDF
Valeant Pharmaceuticals International, Inc. Announces Additional Information Regarding Continuance Proposal Date 05/10/13 Title Valeant Pharmaceuticals International, Inc. Announces Additional Information Regarding Continuance Proposal Download PDF
Valeant Pharmaceuticals Provides Efinconazole Update Date 05/02/13 Title Valeant Pharmaceuticals Provides Efinconazole Update Download PDF
Valeant Pharmaceuticals Reports 2013 First Quarter Financial Results Date 05/02/13 Title Valeant Pharmaceuticals Reports 2013 First Quarter Financial Results Download PDF
Actavis Acquires Worldwide Rights for Valeant's Metronidazole 1.3% Vaginal Gel Date 05/01/13 Title Actavis Acquires Worldwide Rights for Valeant's Metronidazole 1.3% Vaginal Gel Download PDF
Valeant Pharmaceuticals International, Inc. Completes Tender Offer for Obagi Medical Products, Inc. Date 04/25/13 Title Valeant Pharmaceuticals International, Inc. Completes Tender Offer for Obagi Medical Products, Inc. Download PDF
Valeant Pharmaceuticals International, Inc. Announces Receipt of Approval From the Antimonopoly Committee of Ukraine for its Previously Announced Acquisition of Obagi Medical Products, Inc. Date 04/24/13 Title Valeant Pharmaceuticals International, Inc. Announces Receipt of Approval From the Antimonopoly Committee of Ukraine for its Previously Announced Acquisition of Obagi Medical Products, Inc. Download PDF
Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc. Date 04/23/13 Title Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc. Download PDF
Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance In The United States For Its Previously Announced Acquisition Of Obagi Medical Products, Inc. Date 04/22/13 Title Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance In The United States For Its Previously Announced Acquisition Of Obagi Medical Products, Inc. Download PDF
Valeant Pharmaceuticals To Announce 2013 First Quarter Results On May 2, 2013 Date 04/16/13 Title Valeant Pharmaceuticals To Announce 2013 First Quarter Results On May 2, 2013 Download PDF
Actavis Reaches Agreements with Valeant to Launch Generic Versions of Ziana® and Zyclara® Date 04/10/13 Title Actavis Reaches Agreements with Valeant to Launch Generic Versions of Ziana® and Zyclara® Download PDF
Actavis and Valeant Announce Actavis as Exclusive Authorized Generic Marketer of Zovirax® Ointment; Co-Promotion Agreements on Zovirax® Cream and Cordran® Tape Date 04/05/13 Title Actavis and Valeant Announce Actavis as Exclusive Authorized Generic Marketer of Zovirax® Ointment; Co-Promotion Agreements on Zovirax® Cream and Cordran® Tape Download PDF
Valeant Pharmaceuticals Provides Update to Recent Event Date 04/04/13 Title Valeant Pharmaceuticals Provides Update to Recent Event Download PDF
Valeant Pharmaceuticals And Obagi Medical Products Agree On An Increased Offer Price Of $24.00 Per Share In Cash Date 04/03/13 Title Valeant Pharmaceuticals And Obagi Medical Products Agree On An Increased Offer Price Of $24.00 Per Share In Cash Download PDF
Valeant Pharmaceuticals Announces Private Exchange Offer Date 03/29/13 Title Valeant Pharmaceuticals Announces Private Exchange Offer Download PDF
Valeant Pharmaceuticals International, Inc. Agrees to Acquire Obagi Medical Products, Inc. for $19.75 Per Share in Cash Date 03/20/13 Title Valeant Pharmaceuticals International, Inc. Agrees to Acquire Obagi Medical Products, Inc. for $19.75 Per Share in Cash Download PDF
Valeant Pharmaceuticals Reports 2012 Fourth Quarter Financial Results Date 02/28/13 Title Valeant Pharmaceuticals Reports 2012 Fourth Quarter Financial Results Download PDF
Valeant Pharmaceuticals Acquires U.S. Rights to Targretin® from Eisai Inc. Date 02/21/13 Title Valeant Pharmaceuticals Acquires U.S. Rights to Targretin® from Eisai Inc. Download PDF
Valeant Completes Acquisition Of Natur Produkt In Russia Date 02/01/13 Title Valeant Completes Acquisition Of Natur Produkt In Russia Download PDF
Valeant Pharmaceuticals To Announce 2012 Fourth Quarter Results On February 28, 2013 Date 01/31/13 Title Valeant Pharmaceuticals To Announce 2012 Fourth Quarter Results On February 28, 2013 Download PDF
Valeant Pharmaceuticals Announces New Management Appointment Date 01/03/13 Title Valeant Pharmaceuticals Announces New Management Appointment Download PDF
Valeant Pharmaceuticals To Present At 31st Annual J.P. Morgan Healthcare Conference Date 01/02/13 Title Valeant Pharmaceuticals To Present At 31st Annual J.P. Morgan Healthcare Conference Download PDF
Valeant Completes Acquisition of Medicis and Announces Date of 2013 Financial Guidance Conference Call Date 12/11/12 Title Valeant Completes Acquisition of Medicis and Announces Date of 2013 Financial Guidance Conference Call Download PDF
Valeant Pharmaceuticals And Galderma Agree On Revised Agreement Terms Date 12/05/12 Title Valeant Pharmaceuticals And Galderma Agree On Revised Agreement Terms Download PDF
Valeant Pharmaceuticals Announces New Management Appointments Date 11/28/12 Title Valeant Pharmaceuticals Announces New Management Appointments Download PDF
Valeant Pharmaceuticals Announces Publication of Efinaconazole Phase III Results Date 11/26/12 Title Valeant Pharmaceuticals Announces Publication of Efinaconazole Phase III Results Download PDF
Valeant Pharmaceuticals Annonces New $1.5 Billion Securites Repurchase Program Date 11/19/12 Title Valeant Pharmaceuticals Annonces New $1.5 Billion Securites Repurchase Program Download PDF
Valeant Pharmaceuticals Receives FTC Clearance For Medicis Acquisition Date 11/16/12 Title Valeant Pharmaceuticals Receives FTC Clearance For Medicis Acquisition Download PDF
Valeant Pharmaceuticals Reports 2012 Third Quarter Financial Results Date 11/02/12 Title Valeant Pharmaceuticals Reports 2012 Third Quarter Financial Results Download PDF
Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash Date 09/03/12 Title Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash Download PDF
Valeant Pharmaceuticals Reports 2012 Second Quarter Financial Results Date 08/02/12 Title Valeant Pharmaceuticals Reports 2012 Second Quarter Financial Results Download PDF
Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012 Date 07/16/12 Title Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012 Download PDF
Valeant Pharmaceuticals to Host Investor Day Date 06/21/12 Title Valeant Pharmaceuticals to Host Investor Day Download PDF
Valeant Pharmaceuticals Agrees To Acquire OraPharma Date 06/15/12 Title Valeant Pharmaceuticals Agrees To Acquire OraPharma Download PDF
Valeant Pharmaceuticals Completes Syndication Of Incremental Term Loans Date 06/14/12 Title Valeant Pharmaceuticals Completes Syndication Of Incremental Term Loans Download PDF
Valeant Pharmaceuticals To Host Investor Day Date 06/07/12 Title Valeant Pharmaceuticals To Host Investor Day Download PDF
Valeant Pharmaceuticals To Syndicate Incremental Term Loans Date 05/30/12 Title Valeant Pharmaceuticals To Syndicate Incremental Term Loans Download PDF
Valeant Pharmaceuticals Agrees to Acquire Certain Assets from Swiss Herbal Date 05/24/12 Title Valeant Pharmaceuticals Agrees to Acquire Certain Assets from Swiss Herbal Download PDF
Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical Date 05/03/12 Title Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical Download PDF
Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results Date 05/03/12 Title Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results Download PDF
Valeant Pharmaceuticals To Webcast 2012 Annual Meeting Of Shareholders Date 04/30/12 Title Valeant Pharmaceuticals To Webcast 2012 Annual Meeting Of Shareholders Download PDF
Valeant Pharmaceuticals to Present at Deutsche Bank Securities, Inc. 37th Annual Health Care Conference Date 04/27/12 Title Valeant Pharmaceuticals to Present at Deutsche Bank Securities, Inc. 37th Annual Health Care Conference Download PDF
Valeant Pharmaceuticals Agrees to Acquire Certain Assets from Atlantis Pharma in Mexico Date 04/18/12 Title Valeant Pharmaceuticals Agrees to Acquire Certain Assets from Atlantis Pharma in Mexico Download PDF
Valeant Pharmaceuticals to Announce 2012 First Quarter Results on May 3, 2012 Date 04/16/12 Title Valeant Pharmaceuticals to Announce 2012 First Quarter Results on May 3, 2012 Download PDF
Valeant Pharmaceuticals to Acquire Pedinol Date 04/12/12 Title Valeant Pharmaceuticals to Acquire Pedinol Download PDF
Valeant to Move Its Global Head Office to Quebec and Establish a New Center of Excellence in Dermatology Date 04/03/12 Title Valeant to Move Its Global Head Office to Quebec and Establish a New Center of Excellence in Dermatology Download PDF
Valeant Pharmaceuticals Agrees to Acquire Natur Produkt in Russia Date 03/26/12 Title Valeant Pharmaceuticals Agrees to Acquire Natur Produkt in Russia Download PDF
Valeant Pharmaceuticals Agrees to Acquire Certain Assets From Gerot Lannach Date 03/13/12 Title Valeant Pharmaceuticals Agrees to Acquire Certain Assets From Gerot Lannach Download PDF
Valeant Pharmaceuticals Acquires a 19.9% Minority Equity Investment in Biotech Company in Brazil Date 03/12/12 Title Valeant Pharmaceuticals Acquires a 19.9% Minority Equity Investment in Biotech Company in Brazil Download PDF
Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results Date 02/27/12 Title Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results Download PDF
Valeant Pharmaceuticals to Acquire Eyetech Date 02/13/12 Title Valeant Pharmaceuticals to Acquire Eyetech Download PDF
Valeant Completes Syndication of Senior Secured Term Loan B Facility Date 02/13/12 Title Valeant Completes Syndication of Senior Secured Term Loan B Facility Download PDF
Valeant Pharmaceuticals to Announce 2011 Fourth Quarter and Full Year Results on February 27, 2012 Date 02/08/12 Title Valeant Pharmaceuticals to Announce 2011 Fourth Quarter and Full Year Results on February 27, 2012 Download PDF
Valeant Pharmaceuticals Completes Divestiture of Generic Dermatology Products to Mylan Date 02/06/12 Title Valeant Pharmaceuticals Completes Divestiture of Generic Dermatology Products to Mylan Download PDF
Valeant Pharmaceuticals Acquires Probiotica in Brazil Date 02/01/12 Title Valeant Pharmaceuticals Acquires Probiotica in Brazil Download PDF
Valeant Pharmaceuticals to Syndicate Senior Secured Term Loan Credit Facility Date 01/30/12 Title Valeant Pharmaceuticals to Syndicate Senior Secured Term Loan Credit Facility Download PDF
Valeant Pharmaceuticals Withdraws Offer for Acquisition of ISTA Pharmaceuticals Inc. Date 01/30/12 Title Valeant Pharmaceuticals Withdraws Offer for Acquisition of ISTA Pharmaceuticals Inc. Download PDF
Valeant Pharmaceuticals Increases Proposed Price for Acquisition of ISTA Pharmaceuticals Inc. to $7.50 Per Share in Cash Date 01/17/12 Title Valeant Pharmaceuticals Increases Proposed Price for Acquisition of ISTA Pharmaceuticals Inc. to $7.50 Per Share in Cash Download PDF
Valeant Pharmaceuticals to Present at 30th Annual J.P. Morgan Healthcare Conference Date 01/06/12 Title Valeant Pharmaceuticals to Present at 30th Annual J.P. Morgan Healthcare Conference Download PDF
Valeant Pharmaceuticals Completes Syndication of Incremental Term Loans Date 12/23/11 Title Valeant Pharmaceuticals Completes Syndication of Incremental Term Loans Download PDF
Valeant Pharmaceuticals to Hold Conference Call to Announce 2012 Financial Guidance Date 12/22/11 Title Valeant Pharmaceuticals to Hold Conference Call to Announce 2012 Financial Guidance Download PDF
Valeant Pharmaceuticals Completes Acquisition of iNova Date 12/22/11 Title Valeant Pharmaceuticals Completes Acquisition of iNova Download PDF
Valeant Pharmaceuticals Completes Acquisition of Dermik Date 12/19/11 Title Valeant Pharmaceuticals Completes Acquisition of Dermik Download PDF
Valeant Pharmaceuticals Proposes to Acquire ISTA Pharmaceuticals Inc. for $6.50 Per Share in Cash Date 12/16/11 Title Valeant Pharmaceuticals Proposes to Acquire ISTA Pharmaceuticals Inc. for $6.50 Per Share in Cash Download PDF
Valeant Announces Successful Results From Phase III Onychomycosis Trials Date 12/16/11 Title Valeant Announces Successful Results From Phase III Onychomycosis Trials Download PDF
Valeant Announces the Completion of the Privatization of Afexa Life Sciences Inc. Date 12/12/11 Title Valeant Announces the Completion of the Privatization of Afexa Life Sciences Inc. Download PDF
Valeant Pharmaceuticals Receives Approval From FTC in Connection With Acquisition of Ortho Dermatologics and Dermik Date 12/12/11 Title Valeant Pharmaceuticals Receives Approval From FTC in Connection With Acquisition of Ortho Dermatologics and Dermik Download PDF
Valeant Pharmaceuticals to Syndicate Incremental Term Loans Date 11/30/11 Title Valeant Pharmaceuticals to Syndicate Incremental Term Loans Download PDF
Valeant Pharmaceuticals Agrees to Acquire iNova Date 11/20/11 Title Valeant Pharmaceuticals Agrees to Acquire iNova Download PDF
Valeant Pharmaceuticals Appoints Howard B. Schiller as Chief Financial Officer Date 11/10/11 Title Valeant Pharmaceuticals Appoints Howard B. Schiller as Chief Financial Officer Download PDF
Valeant Pharmaceuticals Reports 2011 Third Quarter Financial Results Date 11/03/11 Title Valeant Pharmaceuticals Reports 2011 Third Quarter Financial Results Download PDF
Valeant Announces New $1.5 Billion Securities Repurchase Program Date 11/03/11 Title Valeant Announces New $1.5 Billion Securities Repurchase Program Download PDF
Valeant Announces Take-Up of Additional Afexa Shares and Special Meeting of Shareholders of Afexa to Approve Its Privatization Date 10/27/11 Title Valeant Announces Take-Up of Additional Afexa Shares and Special Meeting of Shareholders of Afexa to Approve Its Privatization Download PDF
Valeant Pharmaceuticals Successfully Completes Refinancing of Senior Secured Credit Facilities Date 10/21/11 Title Valeant Pharmaceuticals Successfully Completes Refinancing of Senior Secured Credit Facilities Download PDF
Valeant Pharmaceuticals to Announce 2011 Third Quarter Results on November 3, 2011 Date 10/21/11 Title Valeant Pharmaceuticals to Announce 2011 Third Quarter Results on November 3, 2011 Download PDF
Valeant Announces Results of Friendly Offer for Afexa Life Sciences Inc. Date 10/18/11 Title Valeant Announces Results of Friendly Offer for Afexa Life Sciences Inc. Download PDF
Valeant Announces That Afexa Supports and Recommends Valeant's Increased Offer and Agrees to Certain Amendments to Support Agreement Date 09/30/11 Title Valeant Announces That Afexa Supports and Recommends Valeant's Increased Offer and Agrees to Certain Amendments to Support Agreement Download PDF
Valeant Pharmaceuticals Announces Approval Of Colesevelam Hydrochloride In Canada Date 09/28/11 Title Valeant Pharmaceuticals Announces Approval Of Colesevelam Hydrochloride In Canada Download PDF
Valeant Pharmaceuticals Intends to Raise Offer for Afexa Life Sciences Inc. to $0.85 per Share Date 09/26/11 Title Valeant Pharmaceuticals Intends to Raise Offer for Afexa Life Sciences Inc. to $0.85 per Share Download PDF
Valeant Pharmaceuticals to Refinance Senior Secured Credit Facilities Date 09/26/11 Title Valeant Pharmaceuticals to Refinance Senior Secured Credit Facilities Download PDF
Valeant Pharmaceuticals Announces Second Request from the Federal Trade Commission in Connection with Pending Dermatology Acquisitions Date 09/20/11 Title Valeant Pharmaceuticals Announces Second Request from the Federal Trade Commission in Connection with Pending Dermatology Acquisitions Download PDF
Valeant Pharmaceuticals Announces Mailing of Offer and Take-Over Bid Circular to Shareholders of Afexa Date 09/09/11 Title Valeant Pharmaceuticals Announces Mailing of Offer and Take-Over Bid Circular to Shareholders of Afexa Download PDF
Valeant Pharmaceuticals to Present at Industry Conferences Date 09/02/11 Title Valeant Pharmaceuticals to Present at Industry Conferences Download PDF
Valeant Pharmaceuticals Announces All-Cash Offer to Acquire Afexa Life Sciences Inc. Date 08/30/11 Title Valeant Pharmaceuticals Announces All-Cash Offer to Acquire Afexa Life Sciences Inc. Download PDF
Valeant Pharmaceuticals Announces Increase to Monetary Limit Under Its Securities Repurchase Program Date 08/29/11 Title Valeant Pharmaceuticals Announces Increase to Monetary Limit Under Its Securities Repurchase Program Download PDF
Valeant Pharmaceuticals Files a Notice of Intention to Make a Normal Course Issuer Bid Date 08/23/11 Title Valeant Pharmaceuticals Files a Notice of Intention to Make a Normal Course Issuer Bid Download PDF
Valeant Pharmaceuticals Completes Acquisition of Sanitas Group Date 08/19/11 Title Valeant Pharmaceuticals Completes Acquisition of Sanitas Group Download PDF
Valeant Pharmaceuticals Announces Resignation of Michael Van Every From Valeant's Board of Directors Date 08/18/11 Title Valeant Pharmaceuticals Announces Resignation of Michael Van Every From Valeant's Board of Directors Download PDF
Valeant Pharmaceuticals Reports 2011 Second Quarter Financial Results Date 08/04/11 Title Valeant Pharmaceuticals Reports 2011 Second Quarter Financial Results Download PDF
Valeant Pharmaceuticals Appoints Ronald Farmer to Fill Board Vacancy Date 08/03/11 Title Valeant Pharmaceuticals Appoints Ronald Farmer to Fill Board Vacancy Download PDF
Valeant Pharmaceuticals International, Inc. Date 08/03/11 Title Valeant Pharmaceuticals International, Inc. Download PDF
Valeant Pharmaceuticals Announces Approval of Sublinox® in Canada Date 07/25/11 Title Valeant Pharmaceuticals Announces Approval of Sublinox® in Canada Download PDF
Valeant Pharmaceuticals to Announce 2011 Second Quarter Results on August 4, 2011 Date 07/20/11 Title Valeant Pharmaceuticals to Announce 2011 Second Quarter Results on August 4, 2011 Download PDF
Valeant Pharmaceuticals Announces Distribution Agreement for Zuacta(TM) in Canada Date 07/19/11 Title Valeant Pharmaceuticals Announces Distribution Agreement for Zuacta(TM) in Canada Download PDF
Valeant Pharmaceuticals Agrees to Acquire Ortho Dermatologics Date 07/15/11 Title Valeant Pharmaceuticals Agrees to Acquire Ortho Dermatologics Download PDF
Valeant Pharmaceuticals Agrees to Acquire Dermik Date 07/11/11 Title Valeant Pharmaceuticals Agrees to Acquire Dermik Download PDF
Valeant Pharmaceuticals Announces License Agreement With Meda for North American Rights for Elidel® and Xerese(TM) Date 06/30/11 Title Valeant Pharmaceuticals Announces License Agreement With Meda for North American Rights for Elidel® and Xerese(TM) Download PDF
Valeant and GlaxoSmithKline Announce U.S. FDA Approval of Potiga(TM) (ezogabine) Date 06/13/11 Title Valeant and GlaxoSmithKline Announce U.S. FDA Approval of Potiga(TM) (ezogabine) Download PDF
Valeant Pharmaceuticals Agrees to Acquire Sanitas Group for Approximately EUR314 Million in Cash Date 05/24/11 Title Valeant Pharmaceuticals Agrees to Acquire Sanitas Group for Approximately EUR314 Million in Cash Download PDF
Kinerase® Introduces "Change Your Skin, Change Your Life" Charity Campaign Date 05/16/11 Title Kinerase® Introduces "Change Your Skin, Change Your Life" Charity Campaign Download PDF
Valeant Pharmaceuticals to Webcast 2011 Annual Meeting of Shareholders Date 05/11/11 Title Valeant Pharmaceuticals to Webcast 2011 Annual Meeting of Shareholders Download PDF
Valeant Pharmaceuticals Reports 2011 First Quarter Financial Results Date 05/09/11 Title Valeant Pharmaceuticals Reports 2011 First Quarter Financial Results Download PDF
Valeant Pharmaceuticals Congratulates Teva and Cephalon on Their Transaction Date 05/02/11 Title Valeant Pharmaceuticals Congratulates Teva and Cephalon on Their Transaction Download PDF
Valeant Pharmaceuticals to Announce 2011 First Quarter Results on May 9, 2011 Date 04/29/11 Title Valeant Pharmaceuticals to Announce 2011 First Quarter Results on May 9, 2011 Download PDF
Valeant Pharmaceuticals Announces Letter to Cephalon Stockholders Date 04/21/11 Title Valeant Pharmaceuticals Announces Letter to Cephalon Stockholders Download PDF
Valeant Pharmaceuticals Responds to Cephalon Board's Letter Date 04/21/11 Title Valeant Pharmaceuticals Responds to Cephalon Board's Letter Download PDF
Valeant Pharmaceuticals Announces Redemption of 4.0% Convertible Subordinated Notes Due 2013 Date 04/20/11 Title Valeant Pharmaceuticals Announces Redemption of 4.0% Convertible Subordinated Notes Due 2013 Download PDF
Regulatory Update - GSK and Valeant Respond to FDA on ezogabine Date 04/18/11 Title Regulatory Update - GSK and Valeant Respond to FDA on ezogabine Download PDF
Valeant Pharmaceuticals Adds Corporate Governance Expert Abe Friedman to its Slate of Proposed Cephalon Directors Date 04/18/11 Title Valeant Pharmaceuticals Adds Corporate Governance Expert Abe Friedman to its Slate of Proposed Cephalon Directors Download PDF
Valeant Pharmaceuticals Files Presentation for Cephalon Stockholders Date 04/11/11 Title Valeant Pharmaceuticals Files Presentation for Cephalon Stockholders Download PDF
Meda to License Elidel to Valeant Pharmaceuticals Date 04/07/11 Title Meda to License Elidel to Valeant Pharmaceuticals Download PDF
Valeant Pharmaceuticals Files Preliminary Consent Solicitation Statement With the SEC Date 04/05/11 Title Valeant Pharmaceuticals Files Preliminary Consent Solicitation Statement With the SEC Download PDF
Promius Pharma and Valeant Form Collaboration to Market Cloderm(R) Cream in the United States Date 04/01/11 Title Promius Pharma and Valeant Form Collaboration to Market Cloderm(R) Cream in the United States Download PDF
Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash Date 03/29/11 Title Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash Download PDF
GSK and Valeant Receive European Authorisation for Trobalt (retigabine) Date 03/29/11 Title GSK and Valeant Receive European Authorisation for Trobalt (retigabine) Download PDF
Valeant Pharmaceuticals Extends Contract with J. Michael Pearson as CEO and Appoints Him as Chairman of the Board Date 03/22/11 Title Valeant Pharmaceuticals Extends Contract with J. Michael Pearson as CEO and Appoints Him as Chairman of the Board Download PDF
Valeant Pharmaceuticals Completes Acquisition of PharmaSwiss S.A. Date 03/11/11 Title Valeant Pharmaceuticals Completes Acquisition of PharmaSwiss S.A. Download PDF
Valeant Announces Pricing of Senior Notes Date 03/03/11 Title Valeant Announces Pricing of Senior Notes Download PDF
Valeant Launches Senior Notes Offering Date 03/01/11 Title Valeant Launches Senior Notes Offering Download PDF
Valeant Pharmaceuticals Reports 2010 Fourth Quarter Financial Results Date 02/24/11 Title Valeant Pharmaceuticals Reports 2010 Fourth Quarter Financial Results Download PDF
Valeant Pharmaceuticals to Present at RBC Capital Markets' 2011 Healthcare Conference Date 02/16/11 Title Valeant Pharmaceuticals to Present at RBC Capital Markets' 2011 Healthcare Conference Download PDF
Valeant Pharmaceuticals to Announce 2010 Fourth Quarter and Full Year Results on February 24, 2011 Date 02/15/11 Title Valeant Pharmaceuticals to Announce 2010 Fourth Quarter and Full Year Results on February 24, 2011 Download PDF
Valeant Pharmaceuticals Announces Acquisition of Cholestagel(R) in Canada Date 02/10/11 Title Valeant Pharmaceuticals Announces Acquisition of Cholestagel(R) in Canada Download PDF
Valeant Pharmaceuticals Announces License Of ACZONE(R) (dapsone) Gel 5% In Canada Date 02/08/11 Title Valeant Pharmaceuticals Announces License Of ACZONE(R) (dapsone) Gel 5% In Canada Download PDF
Valeant Launches Senior Notes Offering Date 02/03/11 Title Valeant Launches Senior Notes Offering Download PDF
Valeant Announces Pricing of Senior Notes Date 02/03/11 Title Valeant Announces Pricing of Senior Notes Download PDF
Valeant Pharmaceuticals to Acquire U.S. and Canadian Rights to Zovirax(R) Date 02/03/11 Title Valeant Pharmaceuticals to Acquire U.S. and Canadian Rights to Zovirax(R) Download PDF
Valeant Pharmaceuticals to Acquire PharmaSwiss S.A. Date 02/01/11 Title Valeant Pharmaceuticals to Acquire PharmaSwiss S.A. Download PDF
Regulatory Update - GSK and Valeant Receive Positive Opinion in Europe From the CHMP for Trobalt (Retigabine) Date 01/21/11 Title Regulatory Update - GSK and Valeant Receive Positive Opinion in Europe From the CHMP for Trobalt (Retigabine) Download PDF
Valeant Pharmaceuticals to Present at J.P. Morgan 29th Annual Health Care Conference Date 01/10/11 Title Valeant Pharmaceuticals to Present at J.P. Morgan 29th Annual Health Care Conference Download PDF
Valeant Pharmaceuticals to Hold Conference Call to Announce 2011 Financial Guidance Date 12/21/10 Title Valeant Pharmaceuticals to Hold Conference Call to Announce 2011 Financial Guidance Download PDF
Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO Date 12/20/10 Title Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO Download PDF
Valeant Pharmaceuticals Announces Appointment of Robert A. Ingram and Resignation of William M. Wells as Chairman Date 12/13/10 Title Valeant Pharmaceuticals Announces Appointment of Robert A. Ingram and Resignation of William M. Wells as Chairman Download PDF
GSK and Valeant announce receipt of U.S. FDA Complete Response letter for ezogabine Date 12/01/10 Title GSK and Valeant announce receipt of U.S. FDA Complete Response letter for ezogabine Download PDF
Valeant Pharmaceuticals to Present At Piper Jeffray 22nd Annual Health Care Conference Date 11/23/10 Title Valeant Pharmaceuticals to Present At Piper Jeffray 22nd Annual Health Care Conference Download PDF
Valeant Launches Senior Notes Offering Date 11/18/10 Title Valeant Launches Senior Notes Offering Download PDF
Valeant Announces Pricing of Senior Notes Date 11/18/10 Title Valeant Announces Pricing of Senior Notes Download PDF
Valeant Pharmaceuticals and S.A.C Capital Settle Lawsuit Date 11/04/10 Title Valeant Pharmaceuticals and S.A.C Capital Settle Lawsuit Download PDF
Valeant Announces A $1.5 Billion Securities Repurchase Program Date 11/04/10 Title Valeant Announces A $1.5 Billion Securities Repurchase Program Download PDF
Valeant Pharmaceuticals to Gradient Analytics Settle Lawsuit Date 11/04/10 Title Valeant Pharmaceuticals to Gradient Analytics Settle Lawsuit Download PDF
Valeant Declares Special Dividend and Plans to Create a Special Dividend Reinvestment Plan Date 11/04/10 Title Valeant Declares Special Dividend and Plans to Create a Special Dividend Reinvestment Plan Download PDF
Valeant Pharmaceuticals and Kadmon Announce Strategic   Agreement for Antiviral Therapeutics Date 11/01/10 Title Valeant Pharmaceuticals and Kadmon Announce Strategic   Agreement for Antiviral Therapeutics Download PDF
Valeant Pharmaceuticals to Acquire #2 Suncare Brand in Australia Date 10/29/10 Title Valeant Pharmaceuticals to Acquire #2 Suncare Brand in Australia Download PDF
Valeant Pharmaceuticals to Announce 2010 Third Quarter results on November 4, 2010 Date 10/25/10 Title Valeant Pharmaceuticals to Announce 2010 Third Quarter results on November 4, 2010 Download PDF
Valeant Pharmaceuticals Announces that Alexza Pharmaceuticals Has Received A Complete Response Letter For AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA Date 10/11/10 Title Valeant Pharmaceuticals Announces that Alexza Pharmaceuticals Has Received A Complete Response Letter For AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA Download PDF
Valeant and Biovail Complete Merger Date 09/28/10 Title Valeant and Biovail Complete Merger Download PDF
Valeant and Biovail Announce Results of Special Meetings of Shareholders Date 09/27/10 Title Valeant and Biovail Announce Results of Special Meetings of Shareholders Download PDF
Valeant Pharmaceuticals Announces Redemption and Defeasance of 7.625% Senior Notes Due 2020 and 8.375% Senior Notes Due 2016 Date 09/27/10 Title Valeant Pharmaceuticals Announces Redemption and Defeasance of 7.625% Senior Notes Due 2020 and 8.375% Senior Notes Due 2016 Download PDF
Valeant and Biovail Announce Valeant's Intention to Declare a Special Dividend to Valeant Stockholders upon Obtaining Shareholder Approval, Financing and Satisfaction of Other Closing Conditions Date 09/22/10 Title Valeant and Biovail Announce Valeant's Intention to Declare a Special Dividend to Valeant Stockholders upon Obtaining Shareholder Approval, Financing and Satisfaction of Other Closing Conditions Download PDF
Valeant Announces Pricing of Senior Notes Date 09/22/10 Title Valeant Announces Pricing of Senior Notes Download PDF
Valeant Plans Senior Notes Offering and Begins Arrangement of New Credit Facilities Date 09/09/10 Title Valeant Plans Senior Notes Offering and Begins Arrangement of New Credit Facilities Download PDF
GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine Date 08/30/10 Title GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine Download PDF
Valeant and Biovail Set Date for Shareholders Meetings Date 08/11/10 Title Valeant and Biovail Set Date for Shareholders Meetings Download PDF
Ezogabine, an Investigational Anti-Epileptic Drug, Receives Positive Vote from FDA Advisory Committee Date 08/11/10 Title Ezogabine, an Investigational Anti-Epileptic Drug, Receives Positive Vote from FDA Advisory Committee Download PDF
Biovail Reports Second-Quarter 2010 Financial Results Date 08/05/10 Title Biovail Reports Second-Quarter 2010 Financial Results Download PDF
Biovail Declares Quarterly Dividend Date 08/05/10 Title Biovail Declares Quarterly Dividend Download PDF
Valeant Pharmaceuticals Reports 2010 Second Quarter Financial Results Date 08/02/10 Title Valeant Pharmaceuticals Reports 2010 Second Quarter Financial Results Download PDF
Biovail Announces Second-Quarter 2010 Earnings Release, Conference-Call Details Date 07/23/10 Title Biovail Announces Second-Quarter 2010 Earnings Release, Conference-Call Details Download PDF
Valeant Pharmaceuticals to Announce 2010 Second Quarter Results on August 2, 2010 Date 07/22/10 Title Valeant Pharmaceuticals to Announce 2010 Second Quarter Results on August 2, 2010 Download PDF
Valeant Pharmaceuticals Resumes Shipment of Oxsoralen-Ultra(R) Date 06/23/10 Title Valeant Pharmaceuticals Resumes Shipment of Oxsoralen-Ultra(R) Download PDF
Biovail and MedGenesis Announce Grant from The Michael J. Fox Foundation for the Development of GDNF Date 06/22/10 Title Biovail and MedGenesis Announce Grant from The Michael J. Fox Foundation for the Development of GDNF Download PDF
Valeant and Biovail Agree to Merge Date 06/21/10 Title Valeant and Biovail Agree to Merge Download PDF
Valeant and Biovail Agree to Merge Date 06/21/10 Title Valeant and Biovail Agree to Merge Download PDF
Biovail Enters into License Agreement with Kyowa Hakko Kirin Date 06/03/10 Title Biovail Enters into License Agreement with Kyowa Hakko Kirin Download PDF
Valeant Pharmaceuticals to Host Investor Day Date 06/03/10 Title Valeant Pharmaceuticals to Host Investor Day Download PDF
Valeant Pharmaceuticals Completes Acquisition of Aton Pharma, Inc. Date 05/27/10 Title Valeant Pharmaceuticals Completes Acquisition of Aton Pharma, Inc. Download PDF
Valeant Pharmaceuticals Announces Regulatory Approval of Onsolis(TM) in Canada Date 05/10/10 Title Valeant Pharmaceuticals Announces Regulatory Approval of Onsolis(TM) in Canada Download PDF
Biovail Reports First-Quarter 2010 Financial Results Date 05/06/10 Title Biovail Reports First-Quarter 2010 Financial Results Download PDF
Biovail Announces Increase to Quarterly Dividend Date 05/06/10 Title Biovail Announces Increase to Quarterly Dividend Download PDF
Valeant Pharmaceuticals to Webcast 2010 Annual Meeting of Stockholders Date 05/04/10 Title Valeant Pharmaceuticals to Webcast 2010 Annual Meeting of Stockholders Download PDF
Valeant Pharmaceuticals Reports 2010 First Quarter Financial Results Date 05/03/10 Title Valeant Pharmaceuticals Reports 2010 First Quarter Financial Results Download PDF
Valeant to Acquire Vital Science Corp. in Canada Date 04/28/10 Title Valeant to Acquire Vital Science Corp. in Canada Download PDF
Valeant Pharmaceuticals to Announce 2010 First Quarter Results on May 3, 2010 Date 04/23/10 Title Valeant Pharmaceuticals to Announce 2010 First Quarter Results on May 3, 2010 Download PDF
Biovail Announces First-Quarter 2010 Earnings Release, Conference-Call Details Date 04/22/10 Title Biovail Announces First-Quarter 2010 Earnings Release, Conference-Call Details Download PDF
Valeant to Acquire Pharmaceutical Company in Brazil Date 04/21/10 Title Valeant to Acquire Pharmaceutical Company in Brazil Download PDF
Valeant Pharmaceuticals Announces Pricing of Senior Notes Date 04/07/10 Title Valeant Pharmaceuticals Announces Pricing of Senior Notes Download PDF
Valeant Plans Senior Notes Offering Date 04/06/10 Title Valeant Plans Senior Notes Offering Download PDF
Valeant Announces Increase to Securities Repurchase Program Date 03/30/10 Title Valeant Announces Increase to Securities Repurchase Program Download PDF
Biovail Acquires AMPAKINE(R) Compounds for Treatment of Respiratory Depression Date 03/26/10 Title Biovail Acquires AMPAKINE(R) Compounds for Treatment of Respiratory Depression Download PDF
Valeant to Acquire Branded Generics/OTC Company in Brazil Date 03/19/10 Title Valeant to Acquire Branded Generics/OTC Company in Brazil Download PDF
Valeant Pharmaceuticals Announces Annual Stockholder Meeting Date Date 03/18/10 Title Valeant Pharmaceuticals Announces Annual Stockholder Meeting Date Download PDF
Valeant Pharmaceuticals to Present at Cowen and Company 30th Annual Health Care Conference Date 03/02/10 Title Valeant Pharmaceuticals to Present at Cowen and Company 30th Annual Health Care Conference Download PDF
Valeant Enters Collaboration With Spear Pharmaceuticals Date 03/01/10 Title Valeant Enters Collaboration With Spear Pharmaceuticals Download PDF
Biovail Reports Fourth Quarter, Year-End 2009 Financial Results Date 02/25/10 Title Biovail Reports Fourth Quarter, Year-End 2009 Financial Results Download PDF
Biovail Declares Quarterly Dividend Date 02/25/10 Title Biovail Declares Quarterly Dividend Download PDF
Valeant Pharmaceuticals Reports 2009 Fourth Quarter and Full Year Financial Results Date 02/22/10 Title Valeant Pharmaceuticals Reports 2009 Fourth Quarter and Full Year Financial Results Download PDF
Biovail Comments on Filing of Complaints Date 02/19/10 Title Biovail Comments on Filing of Complaints Download PDF
Biovail Announces Fourth-Quarter 2009 Earnings Release, Conference-Call Details Date 02/12/10 Title Biovail Announces Fourth-Quarter 2009 Earnings Release, Conference-Call Details Download PDF
Biovail Enters into License and Collaboration Agreement with Alexza for AZ-004 Date 02/10/10 Title Biovail Enters into License and Collaboration Agreement with Alexza for AZ-004 Download PDF
Valeant Pharmaceuticals to Announce 2009 Fourth Quarter and Year Results on February 22, 2010 Date 02/08/10 Title Valeant Pharmaceuticals to Announce 2009 Fourth Quarter and Year Results on February 22, 2010 Download PDF
Biovail Comments on Proposed Generic Wellbutrin XL(R) Trial Date 01/22/10 Title Biovail Comments on Proposed Generic Wellbutrin XL(R) Trial Download PDF
Biovail to Present at JPMorgan Healthcare Conference Date 01/06/10 Title Biovail to Present at JPMorgan Healthcare Conference Download PDF
Valeant Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference Date 01/06/10 Title Valeant Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference Download PDF
Valeant Pharmaceuticals to Hold Conference Call to Announce 2010 Financial Guidance Date 01/05/10 Title Valeant Pharmaceuticals to Hold Conference Call to Announce 2010 Financial Guidance Download PDF
2009 Date Title 2009 Download
2008 Date Title 2008 Download